Cerebrolysin vs Cortexin.

Cerebrolysin is a peptide preparation produced by the enzymatic breakdown of purified porcine (pig) brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids. It is manufactured by EVER Neuro Pharma and given by injection or intravenous infusion rather than orally. Marketed as a neurotrophic and neuroprotective agent, it has been studied across acute ischaemic stroke, vascular dementia, Alzheimer's disease and traumatic brain injury. It is one of the most extensively trialed brain-peptide preparations, yet its clinical benefit remains genuinely contested.

Cortexin is a low-molecular-weight polypeptide preparation extracted from the cerebral cortex of cattle and calves. It contains a mixture of short water-soluble peptides (roughly 1 to 10 kDa), amino acids and trace elements, and is supplied as a lyophilized powder reconstituted for intramuscular injection. Developed and marketed primarily in Russia by GEROPHARM, it is positioned as a neurotrophic and neuroprotective agent. It is used clinically within Russia and several neighboring countries for a range of neurological conditions.

Because Cerebrolysin is a complex biological mixture rather than a single molecule, its mechanism is described as pleiotropic. The peptide fraction is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity and neurogenesis. Preclinical work also suggests reduced excitotoxicity, anti-apoptotic signaling and effects on amyloid processing. The precise active components and their targets in humans are not fully defined.

Like other brain-tissue peptide preparations, Cortexin is a complex mixture, so its activity is attributed to the combined effect of many peptide-protein interactions rather than a single molecular target. Proposed mechanisms include support of neuronal energy metabolism, antioxidant and anti-apoptotic effects, and modulation of neurotrophic factors and neurotransmitter systems such as GABA and dopamine. Its low-molecular-weight peptides are claimed to cross the blood-brain barrier. These mechanisms are largely inferred from preclinical models.

Cerebrolysin has been evaluated in numerous randomized controlled trials, and two Cochrane systematic reviews summarize the best available evidence. The 2023 Cochrane review of acute ischaemic stroke concluded that Cerebrolysin probably has little or no beneficial effect on death or clinical outcome, and it flagged a possible increase in non-fatal serious adverse events, rating certainty of evidence as low to moderate. The 2019 Cochrane review of vascular dementia found possible short-term benefits on cognition and global function but did not recommend routine use, citing small trials, short follow-up and high risk of bias. Several included trials were industry-sponsored, which further tempers confidence. Taken together, the clinical picture is mixed and unsettled rather than clearly positive. The underlying trial set has a distinctive geography: a large share of the randomized evidence originates from centers in Eastern Europe, the CIS, China and parts of Asia, often with the manufacturer as sponsor or provider of study drug, and a substantial portion of the earlier literature was published in languages other than English, which complicates independent appraisal. Trial durations are typically short, on the order of weeks of treatment with follow-up rarely extending to a year, and outcome scales differ between studies, which limits pooling. Later work has continued in narrower settings: a randomized pilot study of speech therapy combined with Cerebrolysin for nonfluent aphasia after acute ischaemic stroke was published in Stroke in 2025, and clinical reviews of neuroprotective and neuroregenerative agents after severe traumatic brain injury continue to describe the evidence as inconclusive. What remains unknown is central rather than peripheral: the active components of the mixture are not identified, so batch-to-batch consistency cannot be verified by potency assay against a defined molecule, and no biomarker predicts response. Even so, Cerebrolysin is the best-studied compound in the animal-tissue peptide category by a wide margin, since preparations such as cortexin, thymalin and vilon have no comparable body of randomized evidence and have never been assessed by Cochrane.

The evidence base for Cortexin comes predominantly from Russian-language studies and preclinical models, with limited independent Western validation. A recent preclinical study (Kurkin et al., Biomedicines 2025) reported neurotropic effects in rat models of toxic and traumatic developmental delay. Clinical use is widespread in Russia across pediatric neurology, stroke rehabilitation and cognitive disorders, but large, blinded, international randomized trials indexed in mainstream databases are scarce. As a result, Cortexin has not been subjected to the RCT and Cochrane-level scrutiny applied to Cerebrolysin. Its efficacy claims should therefore be read with caution. The human literature is dominated by multicenter observational programs rather than randomized comparisons: the CORNELia program in chronic cerebrovascular disease with cognitive impairment and the CORTEX program in post-COVID neurological complaints are both described as observational, meaning they lack a concurrent randomized control arm, blinding, and placebo control, so improvement over time cannot be separated from natural recovery, regression to the mean or expectation effects. Comparative studies do exist within the same national literature, for example a comparison with another peptide preparation in the early recovery period after ischaemic stroke, but these are typically single-country, modest in size and published in one journal, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, closely associated with the domestic market for the drug. Preclinical support includes rodent work on antioxidant effects in chronic cerebrovascular insufficiency and a cell-culture study reporting protection of cultured rat sensory neurons from high-glucose injury. Nearly all of this literature originates in the country where the product is registered and marketed, and the manufacturer's involvement in the observational programs is a relevant consideration. What is missing is specific: no independent multinational randomized trial, no Cochrane or comparable systematic review, no published characterization of which peptides in the extract are active, and no external regulatory assessment of the manufacturing and potency standards. Cortexin sits alongside thymalin, vilon and epitalon in resting on single-country literature, while Cerebrolysin, despite its own unresolved questions, has at least been tested in independently reviewed randomized trials.

In trials Cerebrolysin was generally reported as well tolerated, with reactions such as dizziness, headache, agitation, sweating and injection-site effects. Cochrane reviewers noted a possible signal of increased non-fatal serious adverse events in the stroke setting, though this finding was uncertain, and that uncertainty is itself a finding: the trials were not individually powered for safety, adverse-event definitions varied between studies, and reporting completeness differed, so the signal can be neither confirmed nor dismissed from the existing data. As a porcine-derived biological given parenterally, allergic and hypersensitivity reactions are a theoretical concern, and product information in the countries where it is registered describes contraindications including known hypersensitivity, status epilepticus and severe renal impairment. Rapid infusion has been associated with transient reactions such as flushing, dizziness and palpitations. Because the preparation is a complex mixture rather than a single characterized molecule, immunogenicity and lot-to-lot variability are harder to evaluate than for a defined peptide drug. Material obtained outside licensed pharmacy channels adds contamination and counterfeit risk on top of the pharmacological questions, since parenteral products require verified sterility and endotoxin limits. Adequate monitoring in a trial setting includes supervised administration, observation for infusion reactions, renal function assessment, seizure history review and systematic adverse-event capture. It is a clinical product, not a dietary supplement, and any use is a medical decision.

Cortexin is generally described in its clinical literature as well tolerated when given intramuscularly, with hypersensitivity and allergic reactions being the main labeled concern. As a parenteral bovine-derived biological, theoretical risks include allergic reactions and injection-site effects, and the same category concerns apply that attach to any animal-tissue extract given by injection: immunogenicity on repeated courses, dependence on the source herd and purification process for freedom from adventitious agents, and the practical difficulty of proving batch equivalence for a mixture whose active constituents are not defined. Independent long-term safety data from outside its region of use are limited, and the observational design of most human reports means adverse events were collected without a comparator, so background rates cannot be separated from drug-related events. Use in children, which is common in the Russian pediatric neurology setting, has not been evaluated in independently reviewed controlled trials, and pediatric exposure is precisely the situation where an external safety assessment would ordinarily be required. Product acquired outside licensed pharmacy channels carries additional contamination and counterfeit risk, since injectables demand verified sterility and endotoxin control that unregulated supply cannot demonstrate. A trial-grade safety evaluation would include prospective adverse-event capture against a control arm, hypersensitivity monitoring, hepatic and renal laboratory follow-up, and anti-drug antibody testing on repeat courses. It is a prescription clinical product, not a dietary supplement.

Cerebrolysin is not approved by the US FDA and is not marketed in the United States. It is registered and used clinically in a number of countries across Europe, Asia, the CIS and Latin America. This entry is educational only and contains no dosing guidance.

Cortexin is not FDA-approved and is not marketed in the United States or the European Union. It is a registered prescription medicine in Russia and several post-Soviet states. This summary is educational and includes no dosing information.